GlassScriptPhysician profile
Michaela R Overturf
NPI 1144514803
$9,442.71
in general payments reported to CMS, 2019-2025
26 companies · $2,086 in 2025
The $2,086 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $553 · 2021: $1,186 · 2022: $1,626 · 2023: $1,814 · 2024: $1,397 · 2025: $2,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,194 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,193.88 |
| Education | $103.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,337.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $970.88 | 2019-2025 | |
| Lilly USA, LLC | $732.30 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $722.31 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $600.78 | 2019-2025 | |
| Galderma Laboratories, L.P. | $579.74 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| E.R. Squibb & Sons, L.L.C. | $449.68 | 2022-2025 | Sotyktu |
| Amgen INC. | $379.03 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $368.97 | 2023-2025 | Zoryve |
| Incyte Corporation | $361.38 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $359.31 | 2020-2025 | Dupixent |
| Leo Pharma INC. | $336.05 | 2019-2024 | Adbry |
| Pfizer INC. | $304.67 | 2019-2023 | |
| Ucb, INC. | $225.40 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $189.15 | 2019-2023 | Winlevi, Odomzo, Blu-U |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $154.96 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Dermavant Sciences, INC. | $67.80 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.91 | 2022-2023 | |
| Organon LLC | $38.33 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.52 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $25.98 | 2021 | |
| Dermira, INC. | $20.21 | 2019 | |
| Journey Medical Corporation | $15.58 | 2023 | |
| Celgene Corporation | $13.99 | 2019 | |
| Allergan, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Overturf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.